In vitro assessment of farnesoid X receptor antagonism to predict drug-induced liver injury risk

被引:6
作者
Norona, Leah M. [1 ]
Fullerton, Aaron [1 ]
Lawson, Chris [1 ]
Leung, Leslie [1 ]
Brumm, Jochen [2 ]
Kiyota, Tomomi [1 ]
Maher, Jonathan [1 ]
Khojasteh, Cyrus [3 ]
Proctor, William R. [1 ]
机构
[1] Genentech Inc, Safety Assessment, Predict Toxicol, San Francisco, CA 94080 USA
[2] Genentech Inc, Nonclin Biostat, Prod Dev, San Francisco, CA 94080 USA
[3] Genentech Inc, Dept Drug Metab & Pharmacokinet, San Francisco, CA 94080 USA
关键词
DILI; BSEP; FXR antagonism; Hepatotoxicity; Cholestasis; SALT EXPORT PUMP; BILE-ACID; CYTOCHROME-P450; EXPRESSION; INHIBITION; IDENTIFICATION; TRANSPORTERS; DISPOSITION; MODULATORS; DISCOVERY; TOOL;
D O I
10.1007/s00204-020-02804-4
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Drug-induced liver injury (DILI) continues to be a major cause of drug attrition and restrictive labeling. Given the importance of farnesoid X receptor (FXR) in bile acid homeostasis, drug-related FXR antagonism may be an important mechanism of DILI. However, a comprehensive assessment of this phenomenon broadly in the context of DILI is lacking. As such, we used an orthogonal approach comprising a FXR target gene assay in primary human hepatocytes and a commercially available FXR reporter assay to investigate the potential FXR antagonistic effects of an extensive test set of 159 compounds with and without association with clinical DILI. Data were omitted from analysis based on the presence of cytotoxicity to minimize false positive assay signals and other complications in data interpretation. Based on the experimental approaches employed and corresponding data, the prevalence of FXR antagonism was relatively low across this broad DILI test set, with 16-24% prevalence based on individual assay results or combined signals in both assays. Moreover, FXR antagonism was not highly predictive for identifying clinically relevant hepatotoxicants retrospectively, where FXR antagonist classification alone had minimal to moderate predictive value as represented by positive and negative likelihood ratios of 2.24-3.84 and 0.72-0.85, respectively. The predictivity did not increase significantly when considering only compounds with high clinical exposure (maximal or efficacious plasma exposures > 1.0 mu M). In contrast, modest gains in predictive value of FXR antagonism were observed considering compounds that also inhibit bile salt export pump. In addition, we have identified novel FXR antagonistic effects of well-studied hepatotoxic drugs, including bosentan, tolcapone and ritonavir. In conclusion, this work represents a comprehensive evaluation of FXR antagonism in the context of DILI, including its overall predictivity and challenges associated with detecting this phenomenon in vitro.
引用
收藏
页码:3185 / 3200
页数:16
相关论文
共 58 条
  • [41] Early Identification of Clinically Relevant Drug Interactions With the Human Bile Salt Export Pump (BSEP/ABCB11)
    Pedersen, Jenny M.
    Matsson, Par
    Bergstrom, Christel A. S.
    Hoogstraate, Janet
    Noren, Agneta
    LeCluyse, Edward L.
    Artursson, Per
    [J]. TOXICOLOGICAL SCIENCES, 2013, 136 (02) : 328 - 343
  • [42] Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury
    Proctor, William R.
    Foster, Alison J.
    Vogt, Jennifer
    Summers, Claire
    Middleton, Brian
    Pilling, Mark A.
    Shienson, Daniel
    Kijanska, Monika
    Stroebel, Simon
    Kelm, Jens M.
    Morgan, Paul
    Messner, Simon
    Williams, Dominic
    [J]. ARCHIVES OF TOXICOLOGY, 2017, 91 (08) : 2849 - 2863
  • [43] Evaluation of in Vitro Mitochondrial Toxicity Assays and Physicochemical Properties for Prediction of Organ Toxicity Using 228 Pharmaceutical Drugs
    Rana, Payal
    Aleo, Michael D.
    Gosink, Mark
    Will, Yvonne
    [J]. CHEMICAL RESEARCH IN TOXICOLOGY, 2019, 32 (01) : 156 - 167
  • [44] Cytochrome P450 expression in human hepatocytes and hepatoma cell lines:: molecular mechanisms that determine lower expression in cultured cells
    Rodríguez-Antona, C
    Donato, MT
    Boobis, A
    Edwards, RJ
    Watts, PS
    Castell, JV
    Gómez-Lechón, MJ
    [J]. XENOBIOTICA, 2002, 32 (06) : 505 - 520
  • [45] Minimizing DILI risk in drug discovery - A screening tool for drug candidates
    Schadt, S.
    Simon, S.
    Kustermann, S.
    Boess, F.
    McGinnis, C.
    Brink, A.
    Lieven, R.
    Fowler, S.
    Youdim, K.
    Ullah, M.
    Marschmann, M.
    Zihlmann, C.
    Siegrist, Y. M.
    Cascais, A. C.
    Di Lenarda, E.
    Durr, E.
    Schaub, N.
    Ang, X.
    Starke, V.
    Singer, T.
    Alvarez-Sanchez, R.
    Roth, A. B.
    Schuler, F.
    Funk, C.
    [J]. TOXICOLOGY IN VITRO, 2015, 30 (01) : 429 - 437
  • [46] The Identification of Pivotal Transcriptional Factors Mediating Cell Responses to Drugs With Drug-Induced Liver Injury Liabilities
    Shah, Falgun
    Medvedev, Alex
    Wassermann, Anne Mai
    Brodney, Marian
    Zhang, Liying
    Makarov, Sergei
    Stanton, Robert V.
    [J]. TOXICOLOGICAL SCIENCES, 2018, 162 (01) : 177 - 188
  • [47] Setting Clinical Exposure Levels of Concern for Drug-Induced Liver Injury (DILI) Using Mechanistic in vitro Assays
    Shah, Falgun
    Leung, Louis
    Barton, Hugh A.
    Will, Yvonne
    Rodrigues, A. David
    Greene, Nigel
    Aleo, Michael D.
    [J]. TOXICOLOGICAL SCIENCES, 2015, 147 (02) : 500 - 514
  • [48] Inhibition of Human Hepatic Bile Acid Transporters by Tolvaptan and Metabolites: Contributing Factors to Drug-Induced Liver Injury?
    Slizgi, Jason R.
    Lu, Yang
    Brouwer, Kenneth R.
    St Claire, Robert L.
    Freeman, Kimberly M.
    Pan, Maxwell
    Brock, William J.
    Brouwer, Kim L. R.
    [J]. TOXICOLOGICAL SCIENCES, 2016, 149 (01) : 237 - 250
  • [49] Nuclear-receptor-mediated regulation of drug- and bile-acid-transporter proteins in gut and liver
    Staudinger, Jeff L.
    Woody, Sarah
    Sun, Mengxi
    Cui, Wenqi
    [J]. DRUG METABOLISM REVIEWS, 2013, 45 (01) : 48 - 59
  • [50] Sulkowski MS, 2000, JAMA-J AM MED ASSOC, V283, P2526